Organogenesis (NASDAQ:ORGO) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Organogenesis (NASDAQ:ORGO - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.11, Zacks reports. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. During the same period last year, the company earned $0.02 earnings per share. Organogenesis updated its FY 2024 guidance to EPS.

Organogenesis Stock Down 3.6 %

Shares of NASDAQ:ORGO traded down $0.15 on Friday, hitting $3.86. 687,109 shares of the company traded hands, compared to its average volume of 825,173. Organogenesis has a 52 week low of $2.16 and a 52 week high of $4.70. The company has a quick ratio of 2.42, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The stock has a 50 day simple moving average of $2.99 and a 200-day simple moving average of $2.82. The company has a market cap of $511.76 million, a PE ratio of -64.33 and a beta of 1.60.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.